How does colchicine use affect neutrophil/lymphocyte, monocyte/lymphocyte, and platelet/lymphocyte ratios in coronary artery disease?

Abstract

Objective: It is an established medical fact that the reduction of inflammation plays a pivotal role in the development of atherosclerosis. This reduction of inflammation is an accepted treatment strategy for coronary artery disease (CAD). The objective of the present study was to demonstrate the effect of colchicine, a commonly used anti-inflammatory agent, on inflammatory markers. Method: The study comprised a sample of 122 patients diagnosed with CAD, whose medical records were meticulously reviewed. Ratios of neutrophil/lymphocyte, monocyte/lymphocyte, and platelet/lymphocyte were calculated and recorded. Following a period of six months during which colchicine was administered, a recalculation of the values was performed. Results: Prior to the commencement of treatment, the neutrophil/lymphocyte ratio (NLR) (3.99 ± 4.72), monocyte/lymphocyte ratio (MLR) (0.41 ± 0.42), and platelet/lymphocyte ratio (PLR) (129.6 ± 74.1) were observed. Following treatment, a decrease was observed in the neutrophil-to-lymphocyte ratio (NLR) (3.5 ± 3), MLR (0.38 ± 0.28), and PLR (122.6 ± 65). In the post-treatment period, statistically significant decreases were observed NLR, MLR, and PLR compared to pre-treatment levels (p<0.001 for all values). Conclusion: In the present study, a significant decrease in the levels of NLR, MLR and PLR was observed in patients with CAD following the initiation of colchicine treatment.

Keywords

• colchicine
• neutrophil/lymphocyte ratios
• monocyte/lymphocyte ratios
• platelet/lymphocyte ratios
• coronary artery disease

Kolşisin kullanımı koroner arter hastalığında nötrofil/lenfosit, monosit/lenfosit ve trombosit/lenfosit oranlarını nasıl etkiler?

Abstract

Amaç: İnflamasyonun azaltılmasının ateroskleroz gelişiminde çok önemli bir rol oynadığı tıbbi olarak kanıtlanmış bir gerçektir. İnflamasyonun azaltılması, koroner arter hastalığı (KAH) için kabul görmüş bir tedavi stratejisidir. Bu çalışmanın amacı, yaygın olarak kullanılan bir anti-inflamatuar ajan olan kolşisinin inflamatuar belirteçler üzerindeki etkisini göstermektir. Yöntemler: Çalışma, tıbbi kayıtları incelenen KAH tanısı konmuş 122 hastadan oluşan bir örneklemden oluşmaktadır. Nötrofil/lenfosit, monosit/lenfosit ve trombosit/lenfosit oranları gibi inflamasyon belirteçleri hesaplanmış ve kaydedilmiştir. Kolşisin uygulanan altı aylık bir dönemin ardından, değerler yeniden hesaplanmıştır. Sonuçlar: Tedaviye başlamadan önce nötrofil/lenfosit oranı (NLR) (3,99 ± 4,72), monosit/lenfosit oranı (MLR) (0,41 ± 0,42) ve trombosit/lenfosit oranı (PLR) (129,6 ± 74,1), tedaviden sonra NLR'de (3,5±3), MLR'de (0,38±0,28) ve trombosit/lenfosit oranında (PLR) (122,6±65) azalma gözlemlendi. Tedavi sonrası dönemde, tedavi öncesi seviyelere kıyasla nötrofil-lenfosit oranında (NLR), monosit-lenfosit oranında (MLR) ve trombosit-lenfosit oranında (PLR) istatistiksel olarak anlamlı düşüşler gözlemlendi (tüm değerler için p<0,001). Sonuç: Bu çalışmada, koroner arter hastalığı olan hastalarda kolşisin tedavisine başlanmasının ardından NLR, MLR ve PLR düzeylerinde anlamlı bir düşüş gözlemlenmiştir.

Keywords

• kolşisin
• nötrofil lenfosit oranı
• monosit lenfosit oranı
• platelet lenfosit oranı
• koroner arter hastalıpğı.

References

1. 1. Guo X, Ma L. Inflammation in coronary artery disease-clinical implications of novel HDLcholesterol–related inflammatory parameters as predictors. Coronary artery disease. 2023;34(1):66-77.
2. 2. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R. Colchicine for acute gout. Cochrane Database of Systematic Reviews. 2021(8).
3. 3. Meyer-Lindemann U, Mauersberger C, Schmidt AC, et al. Colchicine impacts leukocyte trafficking in atherosclerosis and reduces vascular inflammation. Frontiers in immunology. 2022;13:898690.
4. 4. Huguet E, Maccallini G, Pardini P, et al. Reference values for neutrophil to lymphocyte ratio (NLR), a biomarker of cardiovascular risk, according to age and sex in a Latin American population. Curr Probl Cardiol. 2021;46(3):100422.
5. 5. Piotrowski D, Sączewska-Piotrowska A, Jaroszewicz J, Boroń-Kaczmarska A. Lymphocyte-tomonocyte ratio as the best simple predictor of bacterial infection in patients with liver cirrhosis. International journal of environmental research and public health. 2020;17(5):1727.
6. 6. Vakhshoori M, Nemati S, Sabouhi S, et al. Neutrophil to lymphocyte ratio (NLR) prognostic effects on heart failure; a systematic review and meta-analysis. BMC Cardiovascular Disorders. 2023;23(1):555.
7. 7. Glezeva N, Gilmer JF, Watson CJ, Ledwidge M. A central role for monocyte–platelet interactions in heart failure. Journal of cardiovascular pharmacology and therapeutics. 2016;21(3):245-61.
8. 8. Zheng C-F, Liu W-Y, Zeng F-F, et al. Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury. Critical Care. 2017;21(1):238.

9. 9. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England journal of medicine. 2017;377(12):1119-31.
10. 10. Imazio M, Nidorf M. Colchicine and the heart. European Heart Journal. 2021;42(28):2745-60.
11. 11. Zhang F-S, H e Q -Z, Qin CH, et al. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacologica Sinica. 2022;43(9):2173-90.
12. 12. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). European heart journal. 2024;45(36):3415-537.
13. 13. Niazi S, Krogh Nielsen M, Sørensen TL, Subhi Y. Neutrophil‐to‐lymphocyte ratio in age‐related macular degeneration: a systematic review and meta‐analysis. Acta Ophthalmologica. 2019;97(6):558-66.
14. 14. Pillay J, Kamp VM, Van Hoffen E, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. The Journal of clinical investigation. 2012;122(1):327-36.
15. 15. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert review of cardiovascular therapy. 2013;11(1):55-9.
16. 16. Gritzalis KC, Karamanou M, Androutsos G. Gout in the writings of eminent ancient Greek and Byzantine physicians. Acta medico-historica Adriatica: AMHA. 2011;9(1):83-8.
17. 17. Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145(1):61-78.
18. 18. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annual review of immunology. 2009;27(1):669-92.
19. 19. Chen L, Liu C, Liang T, et al. Monocyte‐to‐ Lymphocyte Ratio Was an Independent Factor of the Severity of Spinal Tuberculosis. Oxidative medicine and cellular longevity. 2022;2022(1):7340330.
20. 20. Liu C-J, Jan H-C, Huang H-S. Risks of carotid artery stenosis and atherosclerotic cardiovascular disease in patients with calcium kidney stone: assessment of systemic inflammatory biomarkers. Journal of Personalized Medicine. 2022;12(10):1697. 21. Shang C-Y, W u J -Z, Ren Y-M, et al. Prognostic significance of absolute monocyte count and lymphocyte to monocyte ratio in mucosa-associated lymphoid tissue (MALT) lymphoma. Annals of Hematology. 2023;102(2):359-67.
21. 22. Hsu Y-C, Yang Y-Y, Tsai I-T. Lymphocyte-tomonocyte ratio predicts mortality in cirrhotic patients with septic shock. The American journal of emergency medicine. 2021;40:70-6.
22. 23. Adane T, Melku M, Ayalew G, et al. Accuracy of monocyte to lymphocyte ratio for tuberculosis diagnosis and its role in monitoring antituberculosis treatment: Systematic review and meta-analysis. Medicine. 2022;101(44):e31539.
23. 24. Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and metaanalysis. Cancer epidemiology, biomarkers & prevention. 2014;23(7):1204-12.
24. 25. Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2015;26(7):680-1.
25. 26. Li W, Liu Q, Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Scientific reports. 2017;7(1):40426.
26. 27. Casazzo M, Pisani L, Md Erfan Uddin RA, et al. The Accuracy of the Passive Leg Raising Test Using the Perfusion Index to Identify Preload Responsiveness—A Single Center Study in a Resource-Limited Setting. Diagnostics.2025;15(1):103.
27. 28. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The role of hematological indices in patients with acute coronary syndrome. Disease Markers. 2017;2017(1):3041565.
28. 29. Monteiro Júnior JGdM, de Oliveira Cipriano Torres D. Hematological parameters as prognostic biomarkers in patients with cardiovascular diseases. Current cardiology reviews. 2019;15(4):274-82.
29. 30. Trakarnwijitr I, Li B, Adams H, et al. Agemodulates the relationship between platelet-tolymphocyte ratio and coronary artery disease. International Journal of Cardiology. 2017;248:349- 54.